# AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Study · id `cardio:ct-nct07400107` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07400107](<https://clinicaltrials.gov/study/NCT07400107>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07400107

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 985 participants.

## Technical summary

Registry record NCT07400107. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-20 (actual); primary completion 2028-12-19 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 985 participants (enrolled count; ClinicalTrials.gov record NCT07400107, source copy `cardio:ctgov-nct07400107-2026-11-10`, retrieved 2026-11-18)
- Started: 2026-05-20 (actual) (ClinicalTrials.gov record NCT07400107, source copy `cardio:ctgov-nct07400107-2026-11-10`, retrieved 2026-11-18)
- Primary completion: 2028-12-19 (anticipated) (ClinicalTrials.gov record NCT07400107, source copy `cardio:ctgov-nct07400107-2026-11-10`, retrieved 2026-11-18)
- Completion: 2028-12-19 (anticipated) (ClinicalTrials.gov record NCT07400107, source copy `cardio:ctgov-nct07400107-2026-11-10`, retrieved 2026-11-18)
- Countries: United States; Argentina; Brazil; Bulgaria; Croatia; Germany; Hungary; India; Mexico; Poland; Portugal; Romania; Thailand; Türkiye (ClinicalTrials.gov record NCT07400107, source copy `cardio:ctgov-nct07400107-2026-11-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07400107-2026-11-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- Acronym: AMAZE 8
- Condition: Obesity
- Condition: Overweight
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): NNC0487-0111
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo (matched to NNC0487-0111)
- Intervention (Drug): Placebo (matched to semaglutide)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: aaa731bbf5e12566921af013e0b6159badc008563e18b0a663981b0ad814ffe0
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
